Clinical trials: Hypobetalipoproteinemia
Hypercholesterolemia
(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use…
- Trial name
- FUTURA (NCT00526058)
- Testing
- Secura then Futura, Futura then Secura
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- B. Braun Medical Inc.
Healthy
A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects
To assess the electrocardiogram (ECG) effects of mipomersen administered as a 200-mg subcutaneous (SC) therapeutic and a 200-mg intravenous (IV; [2-hour infusion]) supra-therapeutic dose relative to placebo in healthy adult male…
- Trial name
- NCT01090661
- Testing
- mipomersen sodium, moxifloxacin hydrochloride (Avelox®)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kastle Therapeutics, LLC
Atherosclerotic Cardiovascular Disease (ASCVD)
Target-Oriented Strategy of Ultra-Low LDL-C (<1.0 vs. 1.0-1.39 mmol/L) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment
The goal of this clinical trial is to learn whether an ultra-low LDL-C target (<1.0 mmol/L) can improve clinical outcomes compared with a moderately low LDL-C target (1.0-1.39 mmol/L) in Chinese patients with extreme-high-risk…
- Trial name
- TARGET-EXTREME (NCT07615296)
- Testing
- Lipid-lowering therapy targeting LDL-C <1.0 mmol/L, Lipid-lowering therapy targeting LDL-C 1.0-1.39 mmol/L
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Beijing Anzhen Hospital
Familial Hypobetalipoproteinemia
Prevalence of fAmilial hypobetalipopRoTeinemIa in psychiaTrIc pOpulatioN (PARTITION)
The links between low LDL-C levels and psychologic symptoms (psychotic disorders, mood disorders, aggressivity, suicidal risk, etc.) and cognitive deficits (mainly executing functioning) are debated.
- Trial name
- NCT03549637
- Testing
- Psychiatric population
- Where
- France
- Volunteers
- 896 people
- Sponsor
- Nantes University Hospital
Familial Hypobetalipoproteinemia, Familial Hypobetalipoproteinemia - Heterozygous Form
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects
Rationale. ANGPTL3 has been identified as important regulator of lipolysis as well as a determinant of plasma levels of apolipoprotein B-containing lipoproteins.
- Trial name
- NCT05569928
- Testing
- Administration of deuterated compounds for kinetic study
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Marcello Arca
Healthy Volunteer
A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers
Hypercholesterolemia is characterized by markedly elevated low density lipoproteins (LDL). Elevated LDL is a major risk factor for coronary heart disease (CHD).
- Trial name
- NCT01061814
- Testing
- mipomersen
- Where
- Canada
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Kastle Therapeutics, LLC
Adrenal Insufficiency, Cirrhosis
Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
The hepatoadrenal syndrome has been well described in the literature and is known to be associated with poorer outcomes in both stable and critically ill cirrhotic patients.
- Conditions
- Adrenal Insufficiency, Cirrhosis, Spur Cell Anemia, Lecithin Acyltransferase Deficiency
- Trial name
- NCT03368066
- Testing
- Cosyntropin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Virginia
Type 2 Diabetes Mellitus, Cardiovascular Disease
Effects of Achieving Very Low LDL-Cholesterol After Treatment With Statins on Steroidogenesis and Cognition
We aimed to compare the effect of achieving an LDL-cholesterol <70 vs an LDL-cholesterol <100 mg/dL with simvastatin or atorvastatin on adrenal and testicular steroidogenesis, and cognition in diabetic patients.
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, LDL Cholesterol, Cognition
- Trial name
- NCT00522158
- Testing
- simvastatin, atorvastatin
- Sponsor
- Baskent University
Renal Transplantation
Cranoc Lipid Study in Renal Transplantation
Cardiovascular disease after renal transplantation is an important problem. Patients after renal transplantation with low LDL-Levels (<130mg/dl) receive Fluvastatin 80mg/day (or no medication, to look for the cardiovascular…
- Trial name
- NCT00223041
- Testing
- Fluvastatin
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Schleswig-Holstein
Coronary Artery Disease, Dyslipidemias
Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease
Clinical studies with statins have shown that patients that suffered a cardiovascular event have a high residual risk. Residual risk decreases with the attaining of progressive lower LDL-C levels.
- Trial name
- NCT01308203
- Testing
- Extended release niacin/laropiprant
- Where
- Argentina
- Volunteers
- 32 people
- Sponsor
- Daniel A. Siniawski
Hypobetalipoproteinemia
Prevalence Assessment and Characterization of Psychological Disorders Associated With Hypobetalipoproteinemia
Familial hypobetalipoproteinemia (FHBL, OMIM # 1707730) is a genetic disorder heterozygotic of LDL-C metabolism. Clinical manifestation range from asymptomatic patients to metabolic (fatty liver, diabetes) or psychiatric…
- Trial name
- HYPOPSY (NCT02889614)
- Testing
- Hypobetalipoproteinemia diagnosis (LDL-C ≤ 50 mg/dL without hypolipidemic treatment)
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Nantes University Hospital
Primary Intestinal Hypocholesterolemia, Abetalipoproteinemia
CArotenoid in hypoChOlesterolemia
Hypobetalipoproteinemias (HBL) represent a heterogeneous group of disorders characterized by reduced plasma levels of plasmatic lipids (mainly triglycerides, total cholesterol (TC), LDL-cholesterol (LDL-C), and apolipoprotein B…
- Conditions
- Primary Intestinal Hypocholesterolemia, Abetalipoproteinemia, Chylomicron Retention Disease
- Trial name
- CaCo (NCT05208879)
- Testing
- Characterization of carotenoid status and plasma levels of oxidative stress markers in patients (case group only), Characterization, evaluation and comparison of macular pigment density
- Where
- 3 sites in France
- Volunteers
- 10 people
- Sponsor
- Hospices Civils de Lyon
Hypobetalipoproteinemias
Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention
To evaluate the kinetics of intestinal absorption of vitamin E water-soluble form from the classical lipid-soluble form in a population of patients with intestinal malabsorption (hypocholesterolemias family by retention of…
- Trial name
- VEDROP (NCT01457690)
- Testing
- Tocofersolan, tocopherol alpha, Tocofersolan and tocopherol alpha
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Abetalipoproteinemia
Vitamin Replacement in Abetalipoproteinemia
This study will determine whether short term intravenous infusion of vitamins A and E in patients with abetalipoproteinemia can reverse disease symptoms in these patients.
- Trial name
- NCT00004574
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Familial Hypobetalipoproteinaemia - Heterozygous Form, Low-LDL-syndrome
Characterization of Two Novel Mutations in the Apob Gene
The pilot study has the target to evaluate the outcomes of two novel mutations in the gene of Apolipoprotein B (ApoB). ApoB is the main part of the low-density lipoprotein (LDL).
- Trial name
- NCT03963037
- Testing
- Blood draw
- Where
- Austria
- Volunteers
- 16 people
- Sponsor
- Medical University Innsbruck
Cardiovascular Diseases, Heart Diseases
Mechanisms of Low Levels of Apolipoprotein B
To determine mechanisms of low levels of apolipoprotein B.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypobetalipoproteinemia
- Trial name
- NCT00005565
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Coronary Syndrome
PCSK9 Inhibitor on ACS Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese Population
The study is an open-label, multicenter, and randomized study. The objective of this study is to demonstrate the effect of PCSK9 inhibitor on ACS patients with multivessel disease and relatively low LDL-C levels or LDL-C levels…
- Trial name
- NCT05043740
- Testing
- Repatha or Praluent
- Volunteers
- 1,360 people
- Sponsor
- Second Xiangya Hospital of Central South University
Healthy Volunteer
Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
The primary objective of this Phase I exploratory study is to determine the effects of mipomersen on the hepatic production of apolipoprotein-B (apo B) in very low density lipoprotein (VLDL) compared to baseline levels.
- Trial name
- NCT01414881
- Testing
- mipomersen
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kastle Therapeutics, LLC
Type2 Diabetes, Self Efficacy
The Effect of Tele-Nursing Based Motivational Interviewing in Individuals With Type 2 Diabetes:RCT
This study carried out to examine the effect of tele-nursing based motivational interviewing on diabetes self-efficacy, diabetes self-management and metabolic control parameters (Body mass index, waist circumference…
- Conditions
- Type2 Diabetes, Self Efficacy, Self Management, Tele-nursing
- Trial name
- NCT05628259
- Testing
- Tele-Nursing based Motivational Interviewing
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Pamukkale University
Eye Diseases Hereditary, Retinal Disease
Inherited Retinal Degenerative Disease Registry
The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation.
- Conditions
- Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome
- Trial name
- MRTR (NCT02435940)
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Foundation Fighting Blindness